BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 38115002)

  • 1. Can incorporating genotyping data into efficacy estimators improve efficiency of early phase malaria vaccine trials?
    Potter GE; Callier V; Shrestha B; Joshi S; Dwivedi A; Silva JC; Laurens MB; Follmann DA; Deye GA
    Malar J; 2023 Dec; 22(1):383. PubMed ID: 38115002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Can incorporating genotyping data into efficacy estimators improve efficiency of early phase malaria vaccine trials?
    Potter GE; Callier V; Shrestha B; Joshi S; Dwivedi A; Silva JC; Laurens MB; Follmann DA; Deye GA
    Res Sq; 2023 Sep; ():. PubMed ID: 37790581
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Parasite clearance, cure rate, post-treatment prophylaxis and safety of standard 3-day versus an extended 6-day treatment of artemether-lumefantrine and a single low-dose primaquine for uncomplicated Plasmodium falciparum malaria in Bagamoyo district, Tanzania: a randomized controlled trial.
    Mhamilawa LE; Ngasala B; Morris U; Kitabi EN; Barnes R; Soe AP; Mmbando BP; Björkman A; Mårtensson A
    Malar J; 2020 Jun; 19(1):216. PubMed ID: 32576258
    [TBL] [Abstract][Full Text] [Related]  

  • 4. UK malaria treatment guidelines 2016.
    Lalloo DG; Shingadia D; Bell DJ; Beeching NJ; Whitty CJM; Chiodini PL;
    J Infect; 2016 Jun; 72(6):635-649. PubMed ID: 26880088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Primaquine radical cure in patients with Plasmodium falciparum malaria in areas co-endemic for P falciparum and Plasmodium vivax (PRIMA): a multicentre, open-label, superiority randomised controlled trial.
    Thriemer K; Degaga TS; Christian M; Alam MS; Rajasekhar M; Ley B; Hossain MS; Kibria MG; Tego TT; Abate DT; Weston S; Mnjala H; Rumaseb A; Satyagraha AW; Sadhewa A; Panggalo LV; Ekawati LL; Lee G; Anose RT; Kiros FG; Simpson JA; Karahalios A; Woyessa A; Baird JK; Sutanto I; Hailu A; Price RN
    Lancet; 2023 Dec; 402(10417):2101-2110. PubMed ID: 37979594
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of artemether-lumefantrine and chloroquine with and without primaquine for the treatment of Plasmodium vivax infection in Ethiopia: A randomized controlled trial.
    Abreha T; Hwang J; Thriemer K; Tadesse Y; Girma S; Melaku Z; Assef A; Kassa M; Chatfield MD; Landman KZ; Chenet SM; Lucchi NW; Udhayakumar V; Zhou Z; Shi YP; Kachur SP; Jima D; Kebede A; Solomon H; Mekasha A; Alemayehu BH; Malone JL; Dissanayake G; Teka H; Auburn S; von Seidlein L; Price RN
    PLoS Med; 2017 May; 14(5):e1002299. PubMed ID: 28510573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of PfSPZ Vaccine against Plasmodium falciparum via direct venous inoculation in healthy malaria-exposed adults in Mali: a randomised, double-blind phase 1 trial.
    Sissoko MS; Healy SA; Katile A; Omaswa F; Zaidi I; Gabriel EE; Kamate B; Samake Y; Guindo MA; Dolo A; Niangaly A; Niaré K; Zeguime A; Sissoko K; Diallo H; Thera I; Ding K; Fay MP; O'Connell EM; Nutman TB; Wong-Madden S; Murshedkar T; Ruben AJ; Li M; Abebe Y; Manoj A; Gunasekera A; Chakravarty S; Sim BKL; Billingsley PF; James ER; Walther M; Richie TL; Hoffman SL; Doumbo O; Duffy PE
    Lancet Infect Dis; 2017 May; 17(5):498-509. PubMed ID: 28216244
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and tolerability of single low-dose primaquine in a low-intensity transmission area in South Africa: an open-label, randomized controlled trial.
    Raman J; Allen E; Workman L; Mabuza A; Swanepoel H; Malatje G; Frean J; Wiesner L; Barnes KI
    Malar J; 2019 Jun; 18(1):209. PubMed ID: 31234865
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Strategies for understanding and reducing the Plasmodium vivax and Plasmodium ovale hypnozoite reservoir in Papua New Guinean children: a randomised placebo-controlled trial and mathematical model.
    Robinson LJ; Wampfler R; Betuela I; Karl S; White MT; Li Wai Suen CS; Hofmann NE; Kinboro B; Waltmann A; Brewster J; Lorry L; Tarongka N; Samol L; Silkey M; Bassat Q; Siba PM; Schofield L; Felger I; Mueller I
    PLoS Med; 2015 Oct; 12(10):e1001891. PubMed ID: 26505753
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Artemisinin-based combination therapy for treating uncomplicated Plasmodium vivax malaria.
    Gogtay N; Kannan S; Thatte UM; Olliaro PL; Sinclair D
    Cochrane Database Syst Rev; 2013 Oct; 2013(10):CD008492. PubMed ID: 24163021
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of liver-stage clearance by Primaquine on gametocyte carriage of Plasmodium vivax and P. falciparum.
    Wampfler R; Hofmann NE; Karl S; Betuela I; Kinboro B; Lorry L; Silkey M; Robinson LJ; Mueller I; Felger I
    PLoS Negl Trop Dis; 2017 Jul; 11(7):e0005753. PubMed ID: 28732068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized controlled trial of dihydroartemisinin-piperaquine, artesunate-mefloquine and extended artemether-lumefantrine treatments for malaria in pregnancy on the Thailand-Myanmar border.
    Saito M; Carrara VI; Gilder ME; Min AM; Tun NW; Pimanpanarak M; Viladpai-Nguen J; Paw MK; Haohankhunnatham W; Konghahong K; Phyo AP; Chu C; Turner C; Lee SJ; Duanguppama J; Imwong M; Bancone G; Proux S; Singhasivanon P; White NJ; Nosten F; McGready R
    BMC Med; 2021 Jun; 19(1):132. PubMed ID: 34107963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of primaquine dose on the risk of recurrence in patients with uncomplicated Plasmodium vivax: a systematic review and individual patient data meta-analysis.
    Commons RJ; Rajasekhar M; Edler P; Abreha T; Awab GR; Baird JK; Barber BE; Chu CS; Cui L; Daher A; Gonzalez-Ceron L; Grigg MJ; Hwang J; Karunajeewa H; Lacerda MVG; Ladeia-Andrade S; Lidia K; Llanos-Cuentas A; Longley RJ; Pereira DB; Pasaribu AP; Pukrittayakamee S; Rijal KR; Sutanto I; Taylor WRJ; Thanh PV; Thriemer K; Vieira JLF; Watson JA; Zuluaga-Idarraga LM; White NJ; Guerin PJ; Simpson JA; Price RN;
    Lancet Infect Dis; 2024 Feb; 24(2):172-183. PubMed ID: 37748496
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: an open-label randomised trial.
    Smithuis F; Kyaw MK; Phe O; Win T; Aung PP; Oo AP; Naing AL; Nyo MY; Myint NZ; Imwong M; Ashley E; Lee SJ; White NJ
    Lancet Infect Dis; 2010 Oct; 10(10):673-81. PubMed ID: 20832366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of a three-dose regimen of Plasmodium falciparum sporozoite vaccine in adults during an intense malaria transmission season in Mali: a randomised, controlled phase 1 trial.
    Sissoko MS; Healy SA; Katile A; Zaidi I; Hu Z; Kamate B; Samake Y; Sissoko K; Mwakingwe-Omari A; Lane J; Imeru A; Mohan R; Thera I; Guindo CO; Dolo A; Niare K; Koïta F; Niangaly A; Rausch KM; Zeguime A; Guindo MA; Bah A; Abebe Y; James ER; Manoj A; Murshedkar T; Kc N; Sim BKL; Billingsley PF; Richie TL; Hoffman SL; Doumbo O; Duffy PE
    Lancet Infect Dis; 2022 Mar; 22(3):377-389. PubMed ID: 34801112
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo/ex vivo efficacy of artemether-lumefantrine and artesunate-amodiaquine as first-line treatment for uncomplicated falciparum malaria in children: an open label randomized controlled trial in Burkina Faso.
    Lingani M; Bonkian LN; Yerbanga I; Kazienga A; Valéa I; Sorgho H; Ouédraogo JB; Mens PF; Schallig HDFH; Ravinetto R; d'Alessandro U; Tinto H
    Malar J; 2020 Jan; 19(1):8. PubMed ID: 31906948
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ultra-short course, high-dose primaquine to prevent Plasmodium vivax infection following uncomplicated pediatric malaria: A randomized, open-label, non-inferiority trial of early versus delayed treatment.
    Woon SA; Moore BR; Laman M; Tesine P; Lorry L; Kasian B; Yambo P; Yadi G; Pomat W; Batty KT; Salman S; Robinson LJ; Davis TME; Manning L
    Int J Infect Dis; 2023 May; 130():189-195. PubMed ID: 36906121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pyronaridine-artesunate or dihydroartemisinin-piperaquine versus current first-line therapies for repeated treatment of uncomplicated malaria: a randomised, multicentre, open-label, longitudinal, controlled, phase 3b/4 trial.
    West African Network for Clinical Trials of Antimalarial Drugs (WANECAM)
    Lancet; 2018 Apr; 391(10128):1378-1390. PubMed ID: 29606364
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo efficacy of artemether-lumefantrine and chloroquine against Plasmodium vivax: a randomized open label trial in central Ethiopia.
    Hwang J; Alemayehu BH; Reithinger R; Tekleyohannes SG; Takele Teshi ; Birhanu SG; Demeke L; Hoos D; Melaku Z; Kassa M; Jima D; Malone JL; Nettey H; Green M; Poe A; Akinyi S; Udhayakumar V; Kachur SP; Filler S
    PLoS One; 2013; 8(5):e63433. PubMed ID: 23717423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.